Abnormal Pap With Negative HPV

Last Modified: May 12, 2006


Dear OncoLink "Ask The Experts,"

My recent pap results said I have precancerous lesions with mild dysplasia. I have read that HPV causes low-grade squamous intraepithelial lesions in 85% of cases. My test came back negative for HPV, so what else could have caused this?


Christina S. Chu, MD, Assistant Professor of the Division of Gynecologic Oncology at the University of Pennsylvania Health System, responds:

Most cases of dysplasia of the cervix are associated with the HPV virus. Other risk factors, such as cigarette smoking, are also associated with cervical dysplasia and cancer. In some instances, we do not know the cause of the dysplasia. You should be aware that the Pap test is NOT a direct test for the HPV virus. Special tests can be performed on the Pap smear specimen to detect certain types (strains) of "high-risk" HPV that have a strong association with cervical cancer. However, just because this test is negative does not mean that a patient may not have been exposed to a low-risk strain of HPV. Note that there are over 100 types or strains of HPV.

In general, the chances of mild dysplasia going on to become true cervical cancer are very low. In 70-80% of young women, mild dysplasia is cured by the body's immune system within 2 years. You should continue with your colposcopy and follow-up as frequently as your doctor directs.


How to Find the Cancer Resources You Need - Brown Bag Web Chat
by OncoLink Editorial Team
June 15, 2011

7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Histology Can Reduce Cancer Risk After Abnormal Pap Smear

Nov 28, 2015

Histological assessment recommended to reduce women's cervical cancer risk

Viral DNA-Based Testing Can Triage Women With Abnormal Pap

Mar 29, 2013

Research shows it's better than repeat cytology in identifying patients at high risk for cervical cancer

Prevalence of High-Risk HPV, Cytologic Abnormalities ID'd

Dec 29, 2011

U.S. cervical cancer screening trial IDs prevalence of abnormal cytology, high-risk HPV, ≥CIN2